These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 8792346)

  • 21. Breast cancer prevention: a summary of the chemoprevention trial with tamoxifen.
    Gould K; Gates ML; Miaskowski C
    Oncol Nurs Forum; 1994 Jun; 21(5):835-40. PubMed ID: 7937245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gynecologic tumors in tamoxifen-treated women with breast cancer.
    Seoud MA; Johnson J; Weed JC
    Obstet Gynecol; 1993 Aug; 82(2):165-9. PubMed ID: 8393156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tamoxifen and endometrial cancer.
    Segna RA; Dottino PR; Deligdisch L; Cohen CJ
    Mt Sinai J Med; 1992 Oct; 59(5):416-8. PubMed ID: 1435840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indication of hysteroscopy in tamoxifen treated breast cancer patients.
    Taponeco F; Curcio C; Fasciani A; Giuntini A; Artini PG; Fornaciari G; Petraglia F; Genazzani AR
    J Exp Clin Cancer Res; 2002 Mar; 21(1):37-43. PubMed ID: 12071527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between tamoxifen use and high risk endometrial cancer histologic types.
    Bland AE; Calingaert B; Secord AA; Lee PS; Valea FA; Berchuck A; Soper JT; Havrilesky L
    Gynecol Oncol; 2009 Jan; 112(1):150-4. PubMed ID: 18937966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endometrial changes with chronic tamoxifen use.
    Loret de Mola JR
    Curr Opin Obstet Gynecol; 1997 Jun; 9(3):160-4. PubMed ID: 9263698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients.
    Cohen I; Bernheim J; Azaria R; Tepper R; Sharony R; Beyth Y
    Gynecol Oncol; 1999 Oct; 75(1):136-41. PubMed ID: 10502440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of tamoxifen on the female genital tract.
    Senkus-Konefka E; Konefka T; Jassem J
    Cancer Treat Rev; 2004 May; 30(3):291-301. PubMed ID: 15059652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial.
    Chalas E; Costantino JP; Wickerham DL; Wolmark N; Lewis GC; Bergman C; Runowicz CD
    Am J Obstet Gynecol; 2005 Apr; 192(4):1230-7; discussion 1237-9. PubMed ID: 15846210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer?
    Slomovitz BM; Sun CC; Ramirez PT; Bodurka DC; Diaz P; Lu KH
    Obstet Gynecol; 2004 Aug; 104(2):255-60. PubMed ID: 15291996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reducing the risk of breast cancer with tamoxifen in women at increased risk.
    Vogel VG
    J Clin Oncol; 2001 Sep; 19(18 Suppl):87S-92S. PubMed ID: 11560980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.
    Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Coibion M; Bianco AR
    Hum Reprod; 2006 Feb; 21(2):545-53. PubMed ID: 16210385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endometrial cancer: incidence, prognostic factors, diagnosis, and treatment.
    Creasman WT
    Semin Oncol; 1997 Feb; 24(1 Suppl 1):S1-140-S1-50. PubMed ID: 9045311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First do no harm: extending the debate on the provision of preventive tamoxifen.
    Will BP; Nobrega KM; Berthelot JM; Flanagan W; Wolfson MC; Logan DM; Evans WK
    Br J Cancer; 2001 Nov; 85(9):1280-8. PubMed ID: 11720461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tamoxifen for the prevention of breast cancer: no.
    DeGregorio MW; Maenpaa JU; Wiebe VJ
    Important Adv Oncol; 1995; ():175-85. PubMed ID: 7672804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors and the prevention of breast cancer with tamoxifen.
    Morrow M; Jordan VC
    Cancer Surv; 1993; 18():211-29. PubMed ID: 8012998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention Trial.
    Giles K; Flynn PJ; Dalton R; Zera R
    Minn Med; 1993 Dec; 76(12):25-7. PubMed ID: 8127293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Italian study on the chemoprevention of breast cancer with tamoxifen].
    Veronesi U; Costa A; Sacchini V; Luini A; Bonanni B; Veronesi P; Rotmensz N; Boyle P
    Contracept Fertil Sex; 1995 Apr; 23(4):258-60. PubMed ID: 7757133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival impact of tamoxifen use for breast cancer risk reduction: projections from a patient-specific Markov model.
    Col NF; Goldberg RJ; Orr RK; Erban JK; Fortin JM; Chlebowski RT
    Med Decis Making; 2002; 22(5):386-93. PubMed ID: 12365480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Development of endometrial cancer during tamoxifen therapy].
    Rasmussen KL; Nielsen KM
    Ugeskr Laeger; 1991 Sep; 153(38):2638. PubMed ID: 1949276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.